Market Overview

Loewen Ondaatje McCutcheon Reiterates Buy Rating, $7.50 PT on BioMimetic Therapeutics

Related BMTI
UPDATE: Wedbush Terminates Coverage on BioMimetic Therapeutics on Acquisition by Wright Medical
UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT

In a report published Monday, Loewen Ondaatje McCutcheon reiterated its Buy rating and $7.50 price target on BioMimetic Therapeutics (NASDAQ: BMTI).

Loewen Ondaatje McCutcheon noted, “Overall, our views are mixed on the acquisition of BMTI by Wright Medical. On the positive side, the valuation is roughly in line with our base case outlook for BMTI shares if Augment were approved in 2013 (i.e., EV/share of approximately $8.40).”

BioMimetic Therapeutics closed on Friday at $4.15.

Posted-In: Loewen Ondaatje McCutcheonAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (BMTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters